<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cayman Journal - Perspective Therapeutics Inc (CATX)</title>
    <description>Latest news, press releases, and SEC filings for Perspective Therapeutics Inc (CATX)</description>
    <link>https://caymanjournal.com/stock/CATX</link>
    <language>en-us</language>
    
    <copyright>Copyright 2026, Cayman Journal</copyright>
    <managingEditor>editorial@caymanjournal.com (Editorial Team)</managingEditor>
    <webMaster>webmaster@caymanjournal.com (Web Master)</webMaster>
    <lastBuildDate>Mon, 27 Apr 2026 21:45:02 GMT</lastBuildDate>
    <ttl>60</ttl>
    <atom:link href="https://caymanjournal.com/stock/CATX/feed.xml" rel="self" type="application/rss+xml" />
    <image>
      <url>https://caymanjournal.com/logo.png</url>
      <title>Cayman Journal</title>
      <link>https://caymanjournal.com</link>
      <width>144</width>
      <height>144</height>
    </image>

    <item>
      <title>8-K — Perspective Therapeutics, Inc.</title>
      <description># 🧾 What This Document Is 📰
This document is a summary of a Current Report (Form 8-K) filed by Perspective Therapeutics, Inc. It was triggered by the company presenting updated interim data on one of its core drugs at the American Association for Cancer Research (AACR) Annual Meeting in April 2026</description>
      <link>https://caymanjournal.com/stock/CATX/sec-filing/0001193125-26-162578</link>
      <guid isPermaLink="true">https://caymanjournal.com/stock/CATX/sec-filing/0001193125-26-162578</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      
      <category>SEC Filing</category>
      
    </item>
  </channel>
</rss>